drugset

drugset / Trial / NCT00051909

Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease

NCT00051909 ↗

Phase 2 Completed 200 enrolled Eli Lilly and Company

RandomizedParallel-groupDouble-blindTreatment

Summary

Study of an investigational medication for the treatment of Alzheimer's Disease in patients who are not taking Aricept, Reminyl, Exelon.

Timeline

Start: 2002-11
Primary completion: —
Completion: 2003-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MIBAMPATOR	Small molecule	—	—

Indications